909708-65-2

Upstream product

• 1124-11-4 Tetramethylpyrazine 
• 123-32-0 2,5-dimethyl-pyrazine 
• 67-56-1 methanol 
• 24691-47-2 diethyl 2,5-dimethylpyrazine-3,6-dicarboxylate 

Relevant academic research and scientific papers

Synthesis and biological evaluation of tetramethylpyrazine nitrates as potential anti-ischemic stroke agent

Ischemic stroke, resulting from the blockade of cerebral blood vessels, produces neuronal cell damage and death. [(3,5,6-Trimethylpyrazin-2-yl)methyl nitrate hydrochloride] (NT-1), which contains one nitrate group, was previously synthesized and shown good activity to inhibit platelet aggregation. However, NT-1′ sability to release nitric oxide (NO) and dilate blood vessels was not reported. To increase the activity of dilating cerebral blood vessels and increasing blood supply, we designed and synthesized [(3,6-dimethylpyrazine-2,5-diyl)-bis(methylene)dinitrate] (NT-2), which contains two nitrate groups. Both NT-1 and NT-2 were able to release NO in vitro and dilate the isolated rat middle cerebral artery. In addition, they protected against glutamate-induced cortical neurons damage. NT-2 was more potent than NT-1 in dilating blood vessels.

CaC-Ene-Reductases Reduce the CaN Bond of Oximes

Although enzymes have been found for many reactions, there are still transformations for which no enzyme is known. For instance, not a single defined enzyme has been described for the reduction of the CaN bond of an oxime, only whole organisms. Such an enzymatic reduction of an oxime may give access to (chiral) amines. By serendipity, we found that the oxime moiety adjacent to a ketone as well as an ester group can be reduced by ene-reductases (ERs) to an intermediate amino group. ERs are well-known enzymes for the reduction of activated alkenes, as of α,β-unsaturated ketones. For the specific substrate used here, the amine intermediate spontaneously reacts further to tetrasubstituted pyrazines. This reduction reaction represents an unexpected promiscuous activity of ERs expanding the toolkit of transformations using enzymes.

Ligustrazine-phylloline dimer and preparation method and application thereof

Provided is a ligustrazine-phylloline dimer. A structure is shown in a formula (I). The ligustrazine-phylloline dimer is obtained by Michael addition of diamine monohydrochloride (II) and alkaloid under the action of Yb(OTf)3, neutralization to obtain an intermediate (III) and reaction with 2,4-dibromomethyl-3,5-dimethylazine. The dimer has anti-tumor activity.

Pyrazine derivative, and preparation method and medical use thereof

The present invention relates to a pyrazine derivative, and preparation method and medical use thereof. The pyrazine derivative can remove free radicals and suppress calcium overload and has cytoprotective effects, and can be used for the prevention and t

Synthesis technology of 2,5-dihydroxymethyl-3,6-dimethylpyrazine

The invention discloses a synthesis technology of 2,5-dihydroxymethyl-3,6-dimethylpyrazine (liguzinediol). According to the method, ethyl acetoacetate which is used as a raw material undergoes a nitrosation reaction to generate 2-hydroximinoethyl acetoacetate; through palladium-carbon catalytic reduction, condensation and aromatization, 3,6-dimethylpyrazine-2,5-dicarboxylic acid diethyl ester is generated; and finally through reduction, liguzinediol is obtained. The technology has advantages as follows: raw materials are easily available; reaction is mild; operation is simple; separation and purification are easy; and cost is low. The technology is suitable for industrial production.

Design, synthesis, and biological evaluation of novel tetramethylpyrazine derivatives as potential neuroprotective agents

Oxidative stress plays a crucial role in neurological diseases, resulting in excessive production of reactive oxygen species, mitochondrial dysfunction and cell death. In this work, we designed and synthesized a series of tetramethylpyrazine (TMP) derivatives and investigated their abilities for scavenging free radicals and preventing against oxidative stress-induced neuronal damage in vitro. Among them, compound 22a, consisted of TMP, caffeic acid and a nitrone group, showed potent radical-scavenging activity. Compound 22a had broad neuroprotective effects, including rescuing iodoacetic acid-induced neuronal loss, preventing from tert-butylhydroperoxide (t-BHP)-induced neuronal injury. Compound 22a exerted its neuroprotective effect against t-BHP injury via activation of the phosphatidyl inositol 3-kinase (PI3K)/Akt signaling pathway. Furthermore, in a rat model of permanent middle cerebral artery occlusion, compound 22a significantly improved neurological deficits, and alleviated the infarct area and brain edema. In conclusion, our results suggest that compound 22a could be a potential neuroprotective agent for the treatment of neurological disease, particularly ischemic stroke.

2,5-two hydroxymethyl -3,6-dimethyl-pyrazine synthesis and refining method

The invention discloses a synthesis and refining method of 2, 5-dihydroxymethyl-3, 6-dimethyl pyrazine (liguzinediol). According to the method, the liguzinediol is directly generated from 2, 5-dimethyl pyrazine which is taken as a raw material through free radical reaction. The process has the advantages of one-step reaction, mild reaction, simplicity and convenience in operation, short reaction time, low cost, high yield and easiness in separation and purification, and is suitable for industrial production.

APPLICATION OF 2,5 -DIHYDROXYMETHYL -3,6 - DIMETHYL PYRAZINE AND ITS DERIVATES IN PHARMACY

An application of 2,5-dihydroxymethyl-3,6-dimethyl pyrazine and its derivatives in the preparation of drugs for the treatment of, prevention of, and/or protection from heart failure wherein the structural formula of the compound is as follows: